CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Thomas Yau , J.W. Park , Richard S. Finn +17 more 2019 Annals of Oncology 634 citations